Review of NICE Technology Appraisal No.129; Bortezomib monotherapy for relapsed multiple myeloma and No.171; Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy

Proposal to move guidance to the static list

TA129 was issued in October 2007 and TA171 in June 2009.

A decision was made by the Institute’s Guidance Executive in October 2010 to defer the review date for both pieces of guidance to mid-2011. This was subsequently deferred to the present date in order to allow discussions to take place with the Department of Health regarding the patient access schemes relating to both these technologies.

The literature search did not identify any new published clinical evidence which is likely to lead to a change in the recommendations in the current guidance. No changes to existing patient access schemes are currently proposed and no other guidance is in development.  Based on this information it is proposed that both pieces of guidance are placed on the static list.

Topics on the static list may be transferred back to the active list for further consideration if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance. 

Please see appendix A for a full list of the organisations we have contacted. 

March 2012